Treatment of Advanced Sarcomas Improves Thanks to Artificial Intelligence

Advanced soft tissue sarcomas represent a major challenge in oncology due to their rarity and diversity. A recent analysis has revealed key elements to optimize treatments beyond the second therapeutic line, a phase where options become limited and decisions complex.

The study focused on 90 patients with advanced sarcomas who received a third line of treatment or more. Researchers used artificial intelligence tools to identify factors influencing overall survival. It emerged that disease progression under the second line of treatment significantly reduced survival chances. Conversely, patients with liposarcomas or leiomyosarcomas showed prolonged survival. Similarly, a progression-free period of more than one year after the first line of treatment was associated with a better prognosis.

The results also showed that the timing of certain drug administrations had a variable impact. Trabectedin, for example, retained its efficacy even in the fourth line, suggesting it could be used later in the therapeutic journey. In contrast, pazopanib appeared more effective when introduced earlier, as early as the second line. Finally, the combination of gemcitabine and docetaxel showed stable efficacy, regardless of the treatment line.

These observations highlight the importance of the response to previous treatments and the type of tumor in decision-making. They also open avenues for refining the order of therapy administration, based on their mechanism of action and tolerance. Soft tissue sarcomas, although rare, could thus benefit from more personalized strategies, tailored to each patient and each stage of the disease.

Sources and Credits

Source Study

DOI: https://doi.org/10.1007/s40487-026-00446-7

Title: Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study

Journal: Oncology and Therapy

Publisher: Springer Science and Business Media LLC

Authors: Michael Hoberger; Dorit Di Gioia; Romy L. Zuber; Michael Völkl; Sinan E. Güler; Vindi Jurinovic; Markus Albertsmeier; Alexander Klein; Hans Roland Dürr; Nina-Sophie Schmidt–Hegemann; Thomas Knösel; Wolfgang G. Kunz; Michael von Bergwelt–Baildon; Lars H. Lindner; Anton Burkhard–Meier; Luc M. Berclaz